---
author: Harvey Guo
created: 2024-04-05 10:53
modified: 2024-04-05 10:53
aliases: []
share: true
---

- ![[Pasted image 20240405105311.png|Pasted image 20240405105311.png]]<span style="background:rgba(240, 200, 0, 0.2)">Immunotherapy medications often utilize fragments of a monoclonal immunoglobulin rather than the full immunoglobulin</span>; because fragments are smaller, they typically have <span style="background:rgba(240, 200, 0, 0.2)">better tissue penetration and pharmacokinetics</span>.  Fab fragments contain a variable domain and the first constant region from a heavy and light chain; because they do not contain an Fc receptor, Fab fragments cannot trigger cell killing via [[Complement system|complement]] or phagocytosis.
- ![[L69890.jpg|L69890.jpg]]IgG, IgA, and IgD also have a <span style="background:rgba(240, 200, 0, 0.2)">hinge region between the Fab and the Fc fragments.</span>  The hinge region is rich in cysteine and proline amino acids, which <span style="background:rgba(240, 200, 0, 0.2)">provide significant flexibility to the immunoglobulin and allow greater movement of the Fab fragment arms.</span>  Fab fragments with <span style="background:rgba(240, 200, 0, 0.2)">long hinge regions are better able to reach multiple epitopes on an antigen; this increases immunoglobulin avidity because avidity is directly proportional to the number of Fab-antigen interactions.</span>  However, long hinge regions are more susceptible to destruction by bacterial proteases (eg, IgA protease).